CTTQ
Status and phase
Conditions
Treatments
About
This is an open, multi-cohort clinical study. The first phase is a dose escalation study and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the safety and preliminary efficacy of TQB3909 tablets combined with TQB3702 tablets in hematologic malignancy subjects.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subjects voluntarily joined the study, signed informed consent form, and with good compliance.
≥ 18 years old, ≤75 years old (when signing informed consent form); Eastern Cooperative Oncology Group (ECOG) physical status: 0-2; at least 3 months expected survival period.
Subject population:
At least 1 lesion / measurable disease for efficacy evaluation.
The function of main organs is normal.
Female patients of childbearing age should agree to use contraceptive measures during the study period and for at least 6 months after the completion of the study; a negative serum pregnancy test within 7 days prior to study enrollment and must be non-lactating subjects; male patients should agree to use contraception during the study period and for at least 6 months after the completion of the study.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
208 participants in 1 patient group
Loading...
Central trial contact
Yanyan Liu, Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal